■探讨接受新辅助化疗的局部晚期乳腺癌(LABC)患者血脂比值与生存结果之间的关系。
■这项回顾性研究包括接受新辅助化疗的LABC患者。在基线时前瞻性地测量血清脂质水平。甘油三酯与总胆固醇(TG/TC)的关系,评估甘油三酯与高密度脂蛋白(TG/HDL)和甘油三酯与低密度脂蛋白(TG/LDL)的比值与预后的关系。
■高TG/TC患者(调整后的危险比[aHR]=2.47,95%CI:1.10,5.56,p=0.029),TG/HDL(aHR=2.73,95%CI:1.16,6.41,p=0.021)和TG/LDL(aHR=2.50,95%CI:1.11,5.65,p=0.027)比率更可能出现无病生存(DFS)事件。亚组分析表明,在HER2状态阴性或复发风险较高的患者中,血脂比率对预后的影响更为明显(例如,临床III期,Ki67>30%)。此外,较高的脂质比率往往表明早期DFS事件(0〜2年)(TG/TCp=0.021,TG/HDLp=0.046,TG/LDLp<0.001),TG/LDL比率显示出最佳的预测功效(TG/TCvs.TG/HDL与TG/LDL,1年AUC:0.724vs.0.676vs.0.846,2年AUC:0.653vs.0.638vs.0.708)。
■基线血清TG/TC,TG/HDL和TG/LDL比值是接受新辅助治疗的LABC患者的独立预后因素。然而,它们在预测早期DFS事件中的效用值得进一步调查。
■NCT05621564。
UNASSIGNED: To investigate the association between lipid ratios and survival outcomes in patients with locally advanced breast cancer (LABC) undergoing neoadjuvant chemotherapy.
UNASSIGNED: This retrospective study included patients with LABC receiving neoadjuvant chemotherapy. Serum lipid levels were prospectively measured at baseline. Associations of triglyceride to total cholesterol (TG/TC), triglyceride to high-density lipoprotein (TG/HDL) and triglyceride to low-density lipoprotein (TG/LDL) ratios with prognosis were evaluated.
UNASSIGNED: Patients with high TG/TC (adjusted hazard ratio [aHR] = 2.47, 95% CI: 1.10, 5.56, p = 0.029), TG/HDL (aHR = 2.73, 95% CI: 1.16, 6.41, p = 0.021) and TG/LDL (aHR = 2.50, 95% CI: 1.11, 5.65, p = 0.027) ratios were more likely to experience disease-free survival (DFS) events. Subgroup analysis suggested that the prognostic impact of lipid ratios was more pronounced in patients with negative HER2 status or those at a high risk of recurrence (e.g. clinical stage III, Ki67 > 30%). Additionally, higher lipid ratios tended to indicate early DFS events (0 ~ 2 years) (TG/TC p = 0.021, TG/HDL p = 0.046, TG/LDL p < 0.001), and the TG/LDL ratio demonstrated the best predictive efficacy (TG/TC vs. TG/HDL vs. TG/LDL, 1-year AUC: 0.724 vs. 0.676 vs. 0.846, 2-year AUC: 0.653 vs. 0.638 vs. 0.708).
UNASSIGNED: Baseline serum TG/TC, TG/HDL and TG/LDL ratios were independent prognostic factors in patients with LABC undergoing neoadjuvant therapy. However, their utility in predicting the early DFS events warrants further investigation.
UNASSIGNED: NCT05621564.